Fenretinide

Phase 3Small molecule

Fenretinide is one of 832 small molecule programs targeting Chronic Myeloproliferative Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

831

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myeloproliferative DisorderActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Kidney CancerActive, not recruiting

Unspecified Peripheral T-Cell LymphomaActive, not recruiting

Lung CancerActive, not recruiting

Cognitive ImpairmentActive, not recruiting

T-Cell Non-Hodgkin LymphomaActive, not recruiting

Central Nervous System NeoplasmActive, not recruiting

LymphomaActive, not recruiting

Head and Neck Malignant NeoplasiaActive, not recruiting

Chronic Myeloproliferative DisorderPhase 1

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

T-Cell Non-Hodgkin LymphomaPhase 1

Active, not recruiting

Central Nervous System NeoplasmPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Head and Neck Malignant NeoplasiaPhase 2

Active, not recruiting

Showing 10 of 33 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fenretinide

EEastern Cooperative Oncology Group

Phase 3

3 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Spravato

WWim Janssens

Preclinical

2 5

Acupan

YYonsei University

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

T-Cell Non-Hodgkin Lymphoma

NCT04234048

Q4 2028

Phase 1Recruiting

Small Cell Lung Cancer

NCT06922539

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00003099·52 enrolled

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001378·75 enrolled

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002646·1,500 enrolled

Neuroblastoma2 trials

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Completed·NNant Operations Center·Phase 1·NCT00646230·17 enrolled

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00053326·70 enrolled

Ovarian Cancer2 trials

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Terminated·GGynecologic Oncology Group·N/A·NCT00017134·71 enrolled

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

Completed·UUniversity of Arizona·N/A·NCT00098800·40 enrolled

Prostate Cancer2 trials

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00080899·23 enrolled

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

Completed·CCancer Therapeutics Research Group·Phase 2·NCT00077402·50 enrolled

Small Cell Lung Cancer2 trials

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00009971·32 enrolled

A Phase 1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Clinical Activity, Safety Profile, and Pharmacology of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

Recruiting·SSciTech Development, Inc.·Phase 1·NCT06922539·44 enrolled

22 more indications

Lymphoma2 trials

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Unknown status·CCerRx, Inc.·Phase 2·NCT02495415·140 enrolled

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00288067·32 enrolled

Patients With Solid Tumors2 trials

Combination Chemotherapy in Treating Patients With Solid Tumors

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00009932

Fenretinide in Treating Patients With Solid Tumors

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00003250·31 enrolled

Kidney Cancer1 trial

Chemotherapy in Treating Patients With Advanced Kidney Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00011973

Solid Tumors1 trial

Fenretinide in Treating Children With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003191·18 enrolled

Hematologic Cancer1 trial

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Completed·CCalifornia Cancer Consortium·Phase 1·NCT00104923·29 enrolled

Age-Related Macular Degeneration1 trial

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Completed·SSirion Therapeutics, Inc.·Phase 2·NCT00429936·245 enrolled

T-cell non-Hodgkin lymphoma1 trial

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Recruiting·SSciTech Development, Inc.·Phase 1·NCT04234048·46 enrolled

Metastatic Head and Neck Cancer1 trial

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00006471·11 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00102635·1 enrolled

Glioblastoma Multiforme1 trial

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00075491·42 enrolled

Malignant Glioma1 trial

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00006080

Primary Peritoneal Cancer1 trial

Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00026091·40 enrolled

Malignant Solid Tumors1 trial

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Completed·CCalifornia Cancer Consortium·Phase 1·NCT00387504·21 enrolled

Patients With Advanced Solid Tumors1 trial

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00005819·21 enrolled

Obesity1 trial

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Suspended·UUniversity of California, San Diego·Phase 2·NCT00546455·21 enrolled

Cystic Fibrosis1 trial

Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis

Completed·EElias Matouk·Phase 1·NCT02141958·15 enrolled

Bladder Cancer1 trial

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00004154·111 enrolled

Schizophrenia1 trial

Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients

Withdrawn·—·Phase 3·NCT00534898

Leukoplakia1 trial

Fenretinide in Treating Patients With Leukoplakia of the Mouth

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00004161·30 enrolled

Women1 trial

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Terminated·EEuropean Institute of Oncology·Phase 3·NCT01479192·20 enrolled

Recurrent1 trial

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

Terminated·SSouth Plains Oncology Consortium·Phase 1·NCT01187810·3 enrolled

Unspecified4 trials

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

Completed·IIsland Pharmaceuticals·Phase 1·NCT06181760·25 enrolled

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003601·38 enrolled

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00003223·5 enrolled

Show 1 more trial

Fenretinide in Treating Patients With Cervical Neoplasia

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00003075·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Fenretinide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fenretinide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fenretinide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

Fenretinide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Breast Cancer3 trials

Neuroblastoma2 trials

Ovarian Cancer2 trials

Prostate Cancer2 trials

Small Cell Lung Cancer2 trials

Lymphoma2 trials

Patients With Solid Tumors2 trials

Kidney Cancer1 trial

Solid Tumors1 trial

Hematologic Cancer1 trial

Age-Related Macular Degeneration1 trial

T-cell non-Hodgkin lymphoma1 trial

Metastatic Head and Neck Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Glioblastoma Multiforme1 trial

Malignant Glioma1 trial

Primary Peritoneal Cancer1 trial

Malignant Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Obesity1 trial

Cystic Fibrosis1 trial

Bladder Cancer1 trial

Schizophrenia1 trial

Leukoplakia1 trial

Women1 trial

Recurrent1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News